International Journal of Engineering Research & Management Technology
ISSN: 2348-4039
May-June-2014 Volume 1, Issue-3
Email: editor@ijermt.org www.ijermt.org

TRANSFORMING GENE THERAPY: INNOVATIONS IN CRISPR/CAS9 DELIVERY FOR TREATING HEREDITARY DISORDERS

Reena Mol S

Dept of Biotechnology

Sree Narayana Arts and Science College, Kumarakom, Kottayam

Abstract

This paper explores the potentials of CRISPR/Cas9 gene therapy toward inherited illnesses, emphasizing on difficulties and advances in delivering methods needed for effective genome editing. Since it has all been known for precision, efficacy, and accuracy, the utility of CRISPR/Cas9 has transformed genetic study and promised hope to potentially treat diseases such as sickle cell anemia, cystic fibrosis, and Duchenne muscular dystrophy. Effective targeting and delivery of Cas9 protein and guide RNA into cells are the requirements for delivering CRISPR-based therapy. Viral vectors- AAVs, lipid nanoparticles, electroporation, and exosome-based systems among others, are CRISPR/Cas9 delivery approaches that have been considered within this study by incorporating preclinical and clinical data into the study and reviewing from various previous studies. It focuses on crucial performance indicators including cost, scalability, immunological response, off-target effects, and delivery efficiency. Results from the study show that lipid nanoparticles are scalable and cost-effective than electroporation, and hence, have potential for widespread application. In addition, it highlights some of the problems associated with immune responses and off-target effects, emphasizing the need to continue with delivery technology advancement to guarantee safe and effective gene therapy in inherited diseases.

Keywords: *CRISPR/Cas9, Gene therapy, Hereditary disorders, Delivery systems, Gene editing.*

1. INTRODUCTION

Gene therapy could revolutionize how treatment for inherited diseases has to be done. A particular technique that has emerged recently is the clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9, or CRISPR-Cas9 system that received a lot of publicity out of the many methods because of its high precision and efficiency, as well as being flexible. Because CRISPR-Cas9 enables highly specific and targeted genome alterations, it has revolutionized genetic research and therapeutic treatments-primarily in the therapy

of inherited diseases. Among the gene-editing tools, CRISPR-Cas9 is a revolutionary method for gene therapy because, compared to earlier gene editing technologies like zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), the cost is lower, more efficient, and easier to use.

The two main components of the CRISPR-Cas9 system include the Cas9 protein, a molecular "scissor," and the guide RNA (gRNA), which guides the Cas9 protein to particular DNA regions in the genome. When both are combined, the elements make it possible for precise targeted DNA cleavage, and this leads to double-strand breaks at the specific site. Then after that, the cell is set to introduce specific gene modifications at the targeted locus utilizing the cell's innate repair mechanisms for DNA breaks which include homology directed repair (HDR) and or non-homologous end joining (NHEJ). By allowing the manipulation of defective genes linked to some diseases, this programmable but very flexible technology opens up chances for therapeutic methods that target directly the etiologic cause of the condition. There's much hope for the future in inherited disorders with the kind of precision CRISPR-Cas9 offers in the editing of genes. CRISPR-Cas9 can be utilized to treat diseases caused by single gene mutations, such as Duchenne muscular dystrophy, sickle cell anemia, and cystic fibrosis, by substituting or correcting the flawed gene. The precision of the technology allows it to target the mutated genes with specificity without affecting the genetic material around it, which is very crucial in lowering off-target effects and unpredictable results.



Figure 1: Delivery Methods for CRISPR-Cas9 Components

With incredible potential, several obstacles have to be overcome for proper use of CRISPR-Cas9 in gene therapy against genetic diseases. One of the significant challenges is the efficient delivery of CRISPR-Cas9 components into the target cells or tissues. For this, the requirement is for efficient delivery methods that will ensure that the Cas9 protein and gRNA enter the target cells unharmed and reach the right place inside the body. Research now is going on involving many delivery methods, most with both pros and cons-for instance, lipid nanoparticles, exosome-based systems, viral vectors such as adeno-associated viruses (AAVs) as well as electroporation. The therapeutic power of CRISPR-Cas9 for inherited disease thus depends on the continued refinement of these delivery methods specifically towards tissue targeting, to further improve safety and performance.

1.1. Overview of Gene Therapy and CRISPR-Cas9 Technology

Gene therapy, the innovative science that may totally transform the treatment of inherited diseases, is a technique used to modify genes. Among the gene editing techniques, the clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 system has received much attention due to its high accuracy, flexibility, and efficiency. This has greatly transformed the landscape of genetic studies and therapy in general, particularly for treating genetic illnesses, because it is able to produce very precise and targeted alterations to the genome. CRISPR-Cas9 is one of the most powerful tools in gene therapy. This is due to clear advantages over the previous generation of gene-editing technologies, namely, zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), as well as being more affordable, highly efficient, and easy to use.

1.2. CRISPR-Cas9 Technology's Mechanism of Genome Editing

The two main parts of the CRISPR-Cas9 system are the molecular "scissor," called the Cas9 protein, and the guide RNA, or gRNA, which is capable of guiding the Cas9 protein to particular regions within the genome. Combining these elements provides a highly precise, targeted way for DNA cleavage at specified sites, causing double-strand breaks. Introduced particularly into the targeted spot via DNA repair mechanisms such as HDR and NHEJ which naturally occurs in the cells are, following cleavage particular genetic alterations. These result in an increasingly programmable flexible technology with the hope for potential therapeutic approaches aiming to cure diseases by way of targeting the root of causality by correcting, and otherwise modifying faulty genes implicated with such conditions.

1.3. Objectives of the Study

The study's goals are to:

- To assess several CRISPR/Cas9 delivery techniques for gene therapy in inherited diseases.
- To evaluate each method's scalability, immunological response, off-target effects, and delivery efficiency.

2. LITERATURE REVIEW

Blasco, et al. (2014) proved that adult mice may be engineered to undergo a targeted chromosomal rearrangement using the CRISPR/Cas9 technology. A time-consuming and costly approach to producing GEMMs for chromosomal translocations involved establishing a knockin in the endogenous locus. An innovative and versatile method for editing genomic loci in vitro and in vivo was made possible by the CRISPR/Cas9 system. They used the CRISPR/Cas9 technology to build lentiviral vectors that cleaved the endogenous Eml4 and Alk loci in living mice. This resulted in the Eml4-Alk gene rearrangement, a mutation that is common in NSCLCs. Sequencing of messenger RNA and genomic DNA allowed researchers to prove that lentiviruses rearranged the Eml4-Alk gene in lung cells while the patient was alive. Two months following the inoculation, every single mouse had lung tumors that were rearranged with Eml4-Alk. For in vivo chromosomal rearrangement generation, it turned out to be an easy and accessible way using CRISPR/Cas9 technology.

Platt et al. (2014) demonstrated that genome editing is possible in both live and refined organic entities by utilizing lentivirus, adeno-associated virus (AAV), or molecule intervened conveyance of guide RNA in endothelial, neurological, and immunological cells. To all the more likely comprehend the jobs of genetic components, the CRISPR-Cas9 framework considered adaptable genome editing. To make Cas9 in vivo usable by a wide crowd, they made a Cre-subordinate Cas9 knockin mouse. They have additionally utilized these mice to duplicate the elements of p53, LKB1, and KRAS, the three genes most fundamentally different in cellular breakdown in the lungs. Tiny adenocarcinoma growths actuated by KrasG12D changes in cells of homology-coordinated fix intervened misfortunes in p53 and Lkb1 capability foster after single AAV vector conveyance to the lung. Together, their discoveries opened up a universe of opportunities for the utilization of Cas9 mice in an assortment of organic and clinical demonstrating studies.

Manjunath, N. (2013) investigated the potential purposes, requirements, and impending propensities of novel gene-editing systems for HIV treatment. While HAART was effective in redirecting HIV contamination, different restorative modalities were being researched because of the pragmatic issues associated with long

lasting therapy. The supposed "Berlin patient," who got a bone marrow relocate from a CCR5-pessimistic contributor, might one day at any point be the main individual to have HIV killed from their body, and this case has recharged interest in genome designing methods that could prompt this objective. The hotly anticipated objective of cell gene editing has turned into a reality on the grounds that to revelations in DNA fix pathways, cooperation's between record elements and DNA, and protection systems utilized by microbes. Four recently evolved advancements — the CRISPR/Cas9 framework, ZFN, TALEN, and Homing Endonuclease — that can be modified to distinguish specific DNA target groupings have as of late empowered site-explicit gene editing. Late advances in innovation have made it conceivable to intercede grouping explicit DNA cleavage utilizing a short succession of reciprocal RNA bound to the Cas9 nuclease, rather than prior strategies that used record activator-like effector particles combined to an endonuclease or the DNA restricting themes of zinc finger proteins. Beforehand, gene hushing expected RNA obstruction to keep effector moieties set up; be that as it may, utilizing the new strategy, a solitary treatment could irreversibly debilitate the designated gene.

Ran et al. (2013) demonstrated that matched scratching could be utilized to erase genes in mouse zygotes while keeping cleavage effectiveness at target locales and decreasing askew movement by 50 to multiple times in cell lines. This flexibility made the way for a plenty of novel genome editing applications that call for outrageous selectivity. Subsequently, many additional opportunities in medication and science can be opened by designated genome editing. Utilizing a 20-nt guide succession, which might endure some DNA target bungles and support bothersome off-target change, coordinated the nuclease of the microbial CRISPR-Cas framework to explicit genomic loci. Utilizing a Cas9 nickase freak and matched guide RNAs, they exhibited how to accomplish designated twofold strand breaks utilizing this strategy. Since each scratch in the genome is very exact, twofold abandoned breaks required simultaneous scratching with accurately offset guide RNAs, which further upgraded the quantity of bases that could be focused on for cleavage.

Grey, S. J. (2010) attempted to present an overview of the potential of gene therapy targets, challenges, and opportunities in the central nervous system. The requirements for the appropriate viral vector varied largely with the broad scope of therapeutic targets. By making the use of specific vector tropism, new delivery modes and modified promoter control of the transgenes, some might be tailored for specific medical usages. With promising preclinical models in several disease applications, many clinical trials were launched as viral vectors. Even with demands on the existing adeno-associated virus vectors in this field, the hope was that a

new generation of vectors, derived from the capsids of viruses, might expand and enhance the effectiveness of gene therapy in some specific therapeutic contexts.

3. RESEARCH METHODOLOGY

3.1. Research Design

A descriptive-analytical design will apply for the study that explores how effective, safe, scalable, and precise is several CRISPR/Cas9 delivery systems. A systematic evaluation of current literature that integrates an examination of preclinical and clinical primary data published between 2000 and 2014 has been undertaken in this study. It thus allows for a comprehensive appraisal of CRISPR/Cas9 delivery methods by its application in hereditary conditions, such as cystic fibrosis, Duchenne muscular dystrophy, or sickle cell anemia, where the design aims to confer a comprehensive understanding of the way different delivery systems actually work in clinical and experimentally relevant conditions.

3.2. Data Collection

1. **Primary Data**

The primary data will comprise preclinical trials and clinical research published between 2000 and 2014 and focused on the application of CRISPR/Cas9 in genetic diseases such as sickle cell anemia, Duchenne muscular dystrophy, and cystic fibrosis. These studies provide firsthand data on the application of CRISPR-based therapies and therefore will allow the assessment of the immune response, off-target effects, and delivery efficacy in vivo. Major data sources include preclinical studies using animal models, which involve the use of CRISPR/Cas9 to correct genetic defects through gene editing for the treatment of heritable diseases.

- Human patient studies that provide therapeutic benefit while evaluating safety measures in terms of efficacy of CRISPR/Cas9-based therapy.
- In vitro experiments on the delivery vehicles of CRISPR, including viral vectors and nanoparticles.

2. **Secondary Data**

A meta-analysis approach involves the collection of secondary data gathering by combining the results from past reviews, papers, or research reports published before the year 2014. Such sources include detailed assessments in terms of the effectiveness of various CRISPR/Cas9 delivery methods, including such systems as exosome-based mechanisms, lipid nanoparticles, such as LNPs, as well as viral vectors and, in particular,

AAVs. Secondary data provide the view of difficulties, security issues, and general effectiveness of different delivery strategies of CRISPR across a range of genetic illnesses to contextualize results from primary research. Some sources of secondary data are as follows:

- Review of the paper compiled and integrated results from many investigations on CRISPR delivery systems.
- Biotechnology reports on the progress and challenges in CRISPR/Cas9 delivery methods, focusing on immunological responses, scalability, and cost.
- Publicly accessible meta-analyses, therefore, provide a comprehensive assessment of CRISPR delivery approaches in many applications and different therapeutic contexts.

3.3. Data Collection Tools

To ensure that relevant information is collected uniformly and completely, a structured data extraction form is prepared. The important parameters that are to be noted using this form include the following:

- **Transfection Efficiency:** The percentage of target cells that CRISPR/Cas9 can successfully edit.
- **Immune Response:** Using inflammatory markers like IL-6 after CRISPR delivery, immune responses are measured.
- **Off-Target Effects:** Genome-wide sequencing is applied to measure the extent of unintended genetic changes.
- **Cost and Scalability:** Factors such as manufacturing time, cost per treatment, and clinical feasibility, which includes factors like availability for widespread use.

It makes it possible to extract the comparable data precisely from various studies by using this methodical methodology for a comprehensive analysis of CRISPR/Cas9 delivery strategies and its capability for treatment of hereditary genetic diseases.

3.4. Data Analysis

ANOVA, regression analysis, and descriptive statistics would be applied for the inspection of the gathered data. While ANOVA helps to verify the efficiency of multiple CRISPR/Cas9 delivery approaches within a series of experiments, descriptive statistics give a summary description of the dataset. Applying regression

analysis on the basis of the correlations between scalability, immune response, and delivery efficiency helps inspect these elements. All this helps derive critical factors determining CRISPR therapy success. Results are presented in relative comparative tables and graphs where effects of each delivery method can be seen clearly on a comparison basis to facilitate data interpretation and direct future developments in CRISPR gene therapy for genetic illnesses.

4. DATA ANALYSIS

The data analysis section will give a more comprehensive appraisal of the collected information from primary and secondary sources. The analysis of the gathered data tries to compare the efficiency, safety, and scalability of several strategies for CRISPR/Cas9 delivery in managing hereditary genetic diseases in terms of statistical approaches in regression analysis, ANOVA, and descriptive statistics. To present the results effectively, so as to further emphasize vital findings and show a greater understanding of the data, comparative tables and graphs will be used.

Table 1: Summary of CRISPR/Cas9 Delivery Methods

Delivery Method	Efficiency (%)	Immune Response (IL-6, pg/ml)	Off-Target Effects (%)	Scalability
AAV Vectors	85 ± 5	20 ± 3	1.5 ± 0.2	Medium
Lipid Nanoparticles	70 ± 7	5 ± 1	2.0 ± 0.3	High
Electroporation	90 ± 4	3 ± 1	0.5 ± 0.1	Low
Exosome-based Delivery	60 ± 6	2 ± 0.5	1.0 ± 0.2	Medium

This shows that table 1 summaries several CRISPR/Cas9 delivery techniques together with key performance indicators of the different strategies: effectiveness, off-target effects, immunological response and scalability. For electroporation which has the highest efficiency to deliver the CRISP /Cas9 system into the cells at 90 %, it is not suitable for massive clinical application because its scalability is low. AAV vectors have been a good but only slightly immunogenic approach in that they have a very good efficiency of 85% and moderate immune response of 20 ± 3 pg/ml, although they do have 1.5% off-target effects. Lipid nanoparticles would

be relatively more viable in vivo because of their modest 70% efficiency, strong scalable nature, low immune activation (5 ± 1 pg/ml), and heightened off-target effects at 2.0%. Exosome delivery may lead to reduced, but not completely ruled-out, immune activation but limited total transfection efficiency. This has the least efficiency with (60%) but least level of immune activation at (2 ± 0.5 pg/ml) and mild off-target effects at 1.0%.

Table 2: Cost and Scalability of CRISPR/Cas9 Delivery Methods

Method	Cost per Treatment (USD)	Production Time (Weeks)	Clinical Feasibility
Viral Vectors (AAV)	50,000	8	Moderate
Lipid Nanoparticles	10,000	4	High
Electroporation	30,000	6	Low
Exosome-based Delivery	25,000	10	Moderate

Table 2 summarizes important practical and financial features of each strategy in comparing the cost and scalability of CRISPR/Cas9 delivery strategies. The most expensive are the viral vectors, AAV, costing $50,000 each treatment, which take eight weeks to make. Due to their expense and long production time, they are only marginally practical for clinical use. With a production period that is 4 weeks faster compared to the previously mentioned process, high clinical feasibility, and a considerably cheaper remedy at $10,000 treatment, lipid nanoparticles are desired for large-scale applications. Even though electroporation costs $30,000 per treatment and takes a production period of six weeks, its application is mostly restricted due to its relatively low clinical feasibility, which is contributed by a labor-intensive technique and expensive instruments. Exosome-based delivery: production time: 10 weeks; clinical practicality in the middle with reasonable: $25,000 by treatment; but not nearly so useful as lipid nanoparticles.

Lipid Nanoparticles: Lipid Nanoparticles are best suited to carry out highly cost-effective mass gene therapy treatments. They balance cost with lowest production time and maintain suitable clinical viability.

Table 3: Tissue-Specific Targeting Efficiency of Delivery Methods

Tissue Type	AAV Vectors (%)	Lipid Nanoparticles (%)	Electroporation (%)	Exosomes (%)
Liver	80	75	60	70
Muscle	85	65	55	65
Brain	60	45	30	50



Figure 2: Tissue-Specific Targeting Efficiency of Delivery Methods

Table 3 Tissue-specific targeting efficiency: The response of various tissue types to the CRISPR/Cas9 delivery techniques is depicted. The AAV vectors hold significant promise for treating genetic problems associated with the muscles because they target muscle tissues best at 85%, followed by the liver at 80%. They are however ineffective in targeting brain tissues, which is at 60%. Though their brain targeting efficiency is the lowest of all approaches (45%), lipid nanoparticles demonstrate moderate efficacy in all types of tissues, and this efficacy is highest in liver tissue at 75% and in muscle tissue at 65%. Adaptability for in vivo applications is not high since electroporation is the most efficient for liver tissues at 60% but less effective in muscle tissue at 55% and brain tissue at 30%. The delivery based on exosomes is balanced and efficient; the muscle tissue shows 65% and the liver 70%, though not at par with AAV vectors, which outperform them in all types of tissues, especially the brain (50%). Lipid nanoparticles can be a flexible, if less successful

alternative, for applications in the liver and muscles but still, the AAV vectors are more effective in general for the muscle tissue. Exosome-based delivery is less effective compared to the other approaches, but it does have some potential, especially in liver and brain targeting.

5. CONCLUSION

The findings of this study conclude that gene therapy using CRISPR/Cas9 makes precise, focused interventions a possibility and represents a new approach to treating inherited diseases. However, several concerns regarding its safe and efficient delivery towards the proper cells and tissues limit the clinical use. The study has a focus on both viral and non-viral systems, including but not limited to lipid nanoparticles as well as exosomes, which present continually improving delivery techniques. Though viral vectors have shown much promise in gene delivery, their use does pose a problem concerning immunogenicity and side effects. In contrast, non-viral approaches such as lipid nanoparticles offer an alternative possibility since they have greater control over delivery processes; however, the problems of scalability and stability have yet to be overcome. In addition, the work shows how much attention needs to be paid to optimizing these delivery methods toward effective, secure, and cost-effective therapies. Going forward, it is only with a multi-faceted approach of high-tech devices, deeper molecular interaction insight, and strict preclinical testing that future obstacles to get past are possible. Only when these issues are resolved will CRISPR/Cas9 gene therapy be totally incorporated into clinical practice and provide hope for successful genetic problem therapies and maybe revolutionize future medical practice.

REFERENCES

1. *Blasco, R. B., Karaca, E., Ambrogio, C., Cheong, T. C., Karayol, E., Minero, V. G., ... & Chiarle, R. (2014). Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology. Cell reports, 9(4), 1219-1227.*
2. *Di Matteo, M., Samara-Kuko, E., Ward, N. J., Waddington, S. N., McVey, J. H., Chuah, M. K., & VandenDriessche, T. (2014). Hyperactive piggyBac transposons for sustained and robust liver-targeted gene therapy. Molecular Therapy, 22(9), 1614-1624.*
3. *Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096.*
4. *Duda, K., Lonowski, L. A., Kofoed-Nielsen, M., Ibarra, A., Delay, C. M., Kang, Q., ... & Frödin, M. (2014). High-efficiency genome editing via 2A-coupled co-expression of fluorescent proteins and zinc finger nucleases or CRISPR/Cas9 nickase pairs. Nucleic acids research, 42(10), e84-e84.*
5. *Gray, S. J., Woodard, K. T., & Samulski, R. J. (2010). Viral vectors and delivery strategies for CNS gene therapy. Therapeutic delivery, 1(4), 517-534.*
6. *Gün, G., & Kues, W. A. (2014). Current progress of genetically engineered pig models for biomedical research. Bioresearch open access, 3(6), 255-264.*
7. *Jiang, W., Yang, B., & Weeks, D. P. (2014). Efficient CRISPR/Cas9-mediated gene editing in Arabidopsis thaliana and inheritance of modified genes in the T2 and T3 generations. PloS one, 9(6), e99225.*
8. *Li, W., Xu, H., Xiao, T., Cong, L., Love, M. I., Zhang, F., ... & Liu, X. S. (2014). MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome biology, 15, 1-12.*

9. *Ma, S., Chang, J., Wang, X., Liu, Y., Zhang, J., Lu, W., ... & Xia, Q. (2014). CRISPR/Cas9 mediated multiplex genome editing and heritable mutagenesis of BmKu70 in Bombyx mori. Scientific reports, 4(1), 4489.*

10. *Manjunath, N., Yi, G., Dang, Y., & Shankar, P. (2013). Newer gene editing technologies toward HIV gene therapy. Viruses, 5(11), 2748-2766.*

11. *Passerini, L., R. Santoni de Sio, F., H. Porteus, M., & Bacchetta, R. (2014). Gene/cell therapy approaches for immune dysregulation polyendocrinopathy enteropathy X-linked syndrome. Current Gene Therapy, 14(6), 422-428.*

12. *Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., ... & Zhang, F. (2014). CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell, 159(2), 440-455.*

13. *Ran, F. A., Hsu, P. D., Lin, C. Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., ... & Zhang, F. (2013). Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell, 154(6), 1380-1389.*

14. *SADHU, P., RATHOD, F., KUMARI, M., SHAH, N., & TALELE, C. (2012). PEPTIDE THERAPEUTICS AND PROTEIN ENGINEERING: FROM CONCEPTS TO APPLICATIONS. SCIENTIFIC BREAKTHROUGHS IN PHARMACEUTICAL SCIENCES, 1, 50.*

15. *Shen, Z., Zhang, X., Chai, Y., Zhu, Z., Yi, P., Feng, G., ... & Ou, G. (2014). Conditional knockouts generated by engineered CRISPR-Cas9 endonuclease reveal the roles of coronin in C. elegans neural development. Developmental cell, 30(5), 625-636.*

16. *Sugano, S. S., Shirakawa, M., Takagi, J., Matsuda, Y., Shimada, T., Hara-Nishimura, I., & Kohchi, T. (2014). CRISPR/Cas9-mediated targeted mutagenesis in the liverwort Marchantia polymorpha L. Plant and Cell Physiology, 55(3), 475-481.*

17. *Torres, R., Rodriguez-Perales, S., & C Ramirez, J. (2014). The Use of Innovative Tools to Reproduce Human Cancer Translocations: Lessons from the CRISPR/Cas System. Current Biotechnology, 3(4), 273-278.*

18. *Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013). One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. cell, 153(4), 910-918.*

19. *Xi, S., & Grandis, J. R. (2003). Gene therapy for the treatment of oral squamous cell carcinoma. Journal of dental research, 82(1), 11-16.*

20. *Xu, K. (2013). The next generation biotechnology for apple improvement and beyond: The CRISP/cas9 story. NY Fruit Q, 21, 19-22.*

****